GRAIL GRAL
GRAIL, Inc. · Nasdaq · Services-Medical Laboratories
$157.88+4.83%close on Oct. 28, 2026 · volume 1.2M · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 15, 2026 | Joshua J. Ofman Chief Executive Officer, director | Sold 10b5-1 plan | 20,000 | $136.85 $133.12-$138.79 | $2.74 million |
| Oct. 5, 2026 | Andrew John Partridge Chief Growth Officer | Sold | 7,873 | $146.39 | $1.15 million |
| Oct. 5, 2026 | Aaron Freidin Chief Financial Officer | Sold | 23,619 | $146.39 | $3.46 million |
| Sept. 21, 2026 | Aaron Freidin Chief Financial Officer | Sold 10b5-1 plan | 4,100 | $93.34 $92.26-$95.00 | $382,679 |
| Sept. 21, 2026 | Joshua J. Ofman Chief Executive Officer, director | Sold 10b5-1 plan | 61,452 | $97.74 $92.32-$110.00 | $6.01 million |
| Aug. 27, 2026 | Joshua J. Ofman Chief Executive Officer, director | Sold 10b5-1 plan | 5,000 | $85.02 | $425,098 |
| Aug. 27, 2026 | Aaron Freidin Chief Financial Officer | Sold 10b5-1 plan | 7,900 | $85.01 | $671,579 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.